Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (54)	1/17/2000 9:20:00 PM
From: JMarcus	Respond to of 255

I feel quite confident that Aradigm's wet formulation will be applicable to more therapeutic drugs than will Inhale's dry formulation. I recall hearing Inhale representatives arguing from a defensive posture on this point and stressing other benefits of dry powder formulation, such as superior storage, longer shelf life, and superior sterilization (Aradigm has a good counterargument on the last point). According to Aradigm's website at aradigm.com >>Using standard liquid pharmaceutical technology gives the AERx© system these benefits: Pre-existing formulations. Most protein and small-molecule parenteral formulations are already in liquid form. Extensive expertise. There is significant industry expertise in the formulation of protein and small-molecule solutions. Straightforward formulation. Unlike dry-powder formulation--where issues such as denaturation of proteins and maintenance of small-particle size over a product's lifetime are common--liquid drug formulation is straightforward and generally problem-free. Convenient packaging. Liquid drug solutions can be aseptically packaged in easily stored, single-use, disposable doses. Simpler transitions. Manufacturing scale-up and quality control are easier and more expedient than with powder formulations.<< Marc